News & Presentations

UPCOMING EVENTS

There are currently no events to display.

CORPORATE PRESENTATIONS

Date Title Documents

Corporate Presentation – November

Topline Results from Rhopressa® (netarsudil ophthalmic solution) 0.02% Phase 4 Multi-center Open-label Study (MOST)

AR-13324-CS208 Japan Phase 2 Study Topline Results

News Releases

Date Title and Summary Additional Formats
Toggle Summary Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda® in the European Union
-European Commission Decision Anticipated in Approximately Two Months- DURHAM, N.C. --(BUSINESS WIRE)--Nov. 13, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the
View HTML
Toggle Summary Aerie Pharmaceuticals to Participate in the Stifel 2020 Virtual Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 10, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update
Year-to-Date Net Revenues of $58.5 Million Increased 29% over 2019 Third Quarter Net Revenues of $20.1 Million or $77 Per Bottle U.S. Dry Eye Trial Initiated and Japanese Glaucoma Trial Set to Commence Conference Call and Webcast Today, November 5 th , at 5:00 p.m. ET DURHAM, N.C.
View HTML
Toggle Summary Aerie Pharmaceuticals Initiates Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease
-First Patient Dosed in 90-Day Efficacy Trial Named COMET-1- DURHAM, N.C. --(BUSINESS WIRE)--Oct. 29, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of
View HTML
TOP